Bryn Mawr Capital Management LLC Has $1.12 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Bryn Mawr Capital Management LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 16.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,980 shares of the company’s stock after selling 960 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Cencora were worth $1,119,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Hickory Asset Management Inc. acquired a new position in Cencora during the fourth quarter worth $572,000. Sylvest Advisors LLC acquired a new position in Cencora during the fourth quarter worth $1,105,000. Insight Wealth Strategies LLC raised its holdings in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after buying an additional 11,232 shares during the last quarter. Cerity Partners LLC raised its holdings in Cencora by 10.1% during the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after buying an additional 3,610 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its holdings in Cencora by 46.9% during the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock worth $1,403,000 after buying an additional 1,995 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

COR opened at $250.78 on Thursday. The firm has a market cap of $48.63 billion, a P/E ratio of 35.67, a PEG ratio of 1.31 and a beta of 0.49. The firm has a 50-day moving average of $240.27 and a 200 day moving average of $237.56. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora’s payout ratio is currently 31.29%.

Analysts Set New Price Targets

COR has been the topic of several research reports. UBS Group upped their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.